Antifungal Resistance and Emerging Therapeutic Options
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1168
Special Issue Editor
Interests: antifungal resistance; fungal diseases; Candida; Aspergillus
Special Issue Information
Dear Colleagues,
The increased use of antifungal agents for the treatment of invasive fungal diseases results in antifungal resistance worldwide. Resistance to triazoles has been one of the major problems in invasive candidiasis and candidemia. The prevalence of fluconazole-resistance Candida tropicalis and other Candida species is increasing in some particular areas. Furthermore, outbreaks of Candida auris have been reported and hindered the infection control process.
In some countries azole-resistant Aspergillus was reported, particularly cryptic species, such as Aspergillus lentulus. It may be under-reported in other countries. Limited treatment for azole-resistant aspergillosis was associated with higher mortality.
Besides Candida and Aspergillus, other yeasts and molds may be intrinsically resistant to polyene or azole antifungal agents. Lometospora, Scedosporium, and dematiaceous fungi are among the difficult-to-treat fungal pathogens due to their resistant profiles.
Novel antifungal agents with new mechanisms are emerging. Antifungal targets are not only focused on membrane-associated ergosterol or cell-wall-associated beta-D-glucan, but also on the fungal enzymes used for various cellular functions. These are the new paradigm of antifungal therapy for infection caused by resistant fungi.
On the basis of this evidence, this Special Issue will publish papers focusing on fungal infection related to antifungal resistance and novel antifungal agents that can potentially be used to combat these resistant fungal pathogens.
Dr. Methee Chayakulkeeree
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antifungal resistance
- new antifungal
- azole-resistant
- invasive fungal diseases
- Candida
- Aspergillus
- mold infection
- resistance mechanism
